Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Jun 5;136(11):1278-1290.
doi: 10.1097/CM9.0000000000002171.

Potential biomarkers for diagnosis and disease evaluation of idiopathic pulmonary fibrosis

Affiliations
Review

Potential biomarkers for diagnosis and disease evaluation of idiopathic pulmonary fibrosis

Qing Wang et al. Chin Med J (Engl). .

Abstract

Idiopathic pulmonary fibrosis (IPF) is a chronic progressive lung disease characterized by progressive lung fibrogenesis and histological features of usual interstitial pneumonia. IPF has a poor prognosis and presents a spectrum of disease courses ranging from slow evolving disease to rapid deterioration; thus, a differential diagnosis remains challenging. Several biomarkers have been identified to achieve a differential diagnosis; however, comprehensive reviews are lacking. This review summarizes over 100 biomarkers which can be divided into six categories according to their functions: differentially expressed biomarkers in the IPF compared to healthy controls; biomarkers distinguishing IPF from other types of interstitial lung disease; biomarkers differentiating acute exacerbation of IPF from stable disease; biomarkers predicting disease progression; biomarkers related to disease severity; and biomarkers related to treatment. Specimen used for the diagnosis of IPF included serum, bronchoalveolar lavage fluid, lung tissue, and sputum. IPF-specific biomarkers are of great clinical value for the differential diagnosis of IPF. Currently, the physiological measurements used to evaluate the occurrence of acute exacerbation, disease progression, and disease severity have limitations. Combining physiological measurements with biomarkers may increase the accuracy and sensitivity of diagnosis and disease evaluation of IPF. Most biomarkers described in this review are not routinely used in clinical practice. Future large-scale multicenter studies are required to design and validate suitable biomarker panels that have diagnostic utility for IPF.

PubMed Disclaimer

Conflict of interest statement

None.

Figures

Figure 1
Figure 1
Relationships between markers for diagnosis of IPF and the pathogenesis of IPF. AECs: Alveolar epithelial cells; bFGF: Basic fibroblast growth factor; CD: Cluster of differentiation; ECM: Extracellular matrix; EMT: Epithelial-mesenchymal transition; ER: Endoplasmic reticulum; HDACs: Histone deacetylases; Hsp: Heat shock protein; IGF: Insulin-like growth factor; IPF: Idiopathic pulmonary fibrosis; M-CSF: Macrophage colony stimulating factor; PDGF: Platelet-derived growth factor; PLGF: Placental growth factor; PRDX: Peroxiredoxin; TGF-β: Transforming growth factor-β; Th: T helper; VEGF: Vascular endothelial growth factor.

Similar articles

Cited by

References

    1. Wang Q, Xie ZL, Wu Q, Jin ZX, Yang C, Feng J. Role of various imbalances centered on alveolar epithelial cell/fibroblast apoptosis imbalance in the pathogenesis of idiopathic pulmonary fibrosis. Chin Med J 2021; 134:261–274. doi: 10.1097/CM9.0000000000001288. - PMC - PubMed
    1. Solomon JJ, Chung JH, Cosgrove GP, Demoruelle MK, Fernandez-Perez ER, Fischer A, et al. . Predictors of mortality in rheumatoid arthritis-associated interstitial lung disease. Eur Respir J 2016; 47:588–596. doi: 10.1183/13993003.00357-2015. - PubMed
    1. Morell F, Villar A, Montero MÁ, Muñoz X, Colby TV, Pipvath S, et al. . Chronic hypersensitivity pneumonitis in patients diagnosed with idiopathic pulmonary fibrosis: A prospective case-cohort study. Lancet Respir Med 2013; 1:685–694. doi: 10.1016/S2213-2600(13)70191-7. - PubMed
    1. Raghu G, Collard HR, Egan JJ, Martinez FJ, Behr J, Brown KK, et al. . An official ATS/ERS/JRS/ALAT statement: Idiopathic pulmonary fibrosis: Evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med 2011; 183:788–824. doi: 10.1164/rccm.2009-040GL. - PMC - PubMed
    1. Ohta S, Okamoto M, Fujimoto K, Sakamoto N, Takahashi K, Yamamoto H, et al. . The usefulness of monomeric periostin as a biomarker for idiopathic pulmonary fibrosis. PLoS One 2017; 12:e0174547.doi: 10.1371/journal.pone.0174547. - PMC - PubMed